Role of nuclear receptor in the development and progression of primary biliary cholangitis
-
摘要:
原发性胆汁性胆管炎(PBC)是一种原因不明的慢性进行性肝内胆汁淤积性自身免疫性肝病。目前PBC的病因和发病机制尚不完全清楚。核受体是配体依赖性转录因子超家族,通过信号分子与转录应答间构建联系,调控细胞的生长和分化。人类中核受体家族包含48个成员,如过氧化物酶体增殖物激活受体、孕烷X受体、组成型雄烷受体、肝X受体、法尼醇X受体、维生素D受体、糖皮质激素受体等,受到广泛关注。这些核受体在转录水平调节胆汁酸代谢的关键酶和转运体基因,从而调节体内胆汁酸水平及参与炎症反应。而胆汁酸代谢紊乱和炎症的持续可能是PBC发生发展的关键因素。就核受体在PBC发生发展中的研究进展作一综述,为PBC的发病机制和寻找新的治疗靶点提供理论基础。
Abstract:Primary biliary cholangitis(PBC) is an chronic progressive intrahepatic cholestasis autoimmune liver disease with unknown causes, and at present, the etiology and pathogenesis of PBC remain unclear. Nuclear receptor is a ligand-dependent transcription factor superfamily that regulates cell growth and differentiation by establishing a relationship between signal molecules and transcriptional responses.The human nuclear receptor family consists of 48 members, including peroxisome proliferator-activated receptors, pregnane X receptor,constitutive androstane receptor, liver X receptors, farnesoid X receptor, vitamin D receptor, and glucocorticoid receptor, which have attracted wide attention. These nuclear receptors regulate the key enzymes and transporter genes of bile acid metabolism at the transcriptional level and thus regulate the level of bile acid in the body and participate in inflammatory response. Bile acid metabolism disorder and persistent inflammation may be the key factors for the development and progression of PBC. This article reviews the research advances in nuclear receptors in the development and progression of PBC, in order to provide a theoretical basis for exploring the pathogenesis of PBC and new therapeutic targets.
-
[1] WANG L, GERSHWIN ME, WANG FS. Primary biliary cholangitis in China[J]. Curr Opin Gastroenterol, 2016, 32(3):195-203. [2] TANG YM, WANG JP, BAO WM, et al. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis[J]. Int J Mol Med,2015, 36(2):377-385. [3] KRENKEL O, TACKE F. Macrophages in nonalcoholic fatty liver disease:A role model of pathogenic immunometabolism[J]. Semin Liver Dis, 2017, 37(3):189-197. [4] RAMÓN-VZQUEZ A, de la ROSA JV, TABRAUE C, et al.Common and differential transcriptional actions of nuclear receptors liver X receptorsαandβin macrophages[J]. Mol Cell Biol, 2019, 39(5):e00376-18. [5] ENDO-UMEDA K, NAKASHIMA H, KOMINE-AIZAWA S, et al. Liver X receptors regulate hepatic F4/80+CD11b+Kupffer cells/macrophages and innate immune responses in mice[J].Sci Rep, 2018, 8(1):9281. [6] MIAO CM, HE K, LI PZ, et al. LXRαrepresses LPS-induced inflammatory responses by competing with IRF3 for GRIP1 in Kupffer cells[J]. Int Immunopharmacol, 2016, 35:272-279. [7] HIGHAM A, LEA S, PLUMB J, et al. The role of the liver X receptor in chronic obstructive pulmonary disease[J]. Respir Res, 2013, 14:106. [8] ZHAO Q, ZHOU D, YOU H, et al. IFN-γaggravates neointimal hyperplasia by inducing endoplasmic reticulum stress and apoptosis in macrophages by promoting ubiquitin-dependent liver X receptor-αdegradation[J]. FASEB J, 2017, 31(12):5321-5331. [9] DAI B, LEI C, LIN R, et al. Activation of liver X receptorαprotects amyloidβ1-40 induced inflammatory and senescent responses in human retinal pigment epithelial cells[J]. Inflamm Res, 2017, 66(6):523-534. [10] BI X, SONG J, GAO J, et al. Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF-κB pathway and SUMOylation[J]. J Cell Mol Med, 2016, 20(12):2249-2258. [11] CANAVAN M, MCCARTHY C, LARBI NB, et al. Activation of liver X receptor suppresses the production of the IL-12 family of cytokines by blocking nuclear translocation of NF-κBp50[J]. Innate Immun, 2014, 20(7):675-687. [12] POURCET B, GAGE MC, LEÓN TE,et al. The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms[J]. Sci Rep, 2016, 6:25481. [13] XIAO J, CHEN Q, TANG D, et al. Activation of liver X receptors promotes inflammatory cytokine mRNA degradation by upregulation of tristetraprolin[J]. Acta Biochim Biophys Sin(Shanghai), 2017, 49(3):277-283. [14] LEI C, LIN R, WANG J, et al. Amelioration of amyloidβ-induced retinal inflammatory responses by a LXR agonist TO901317 is associated with inhibition of the NF-κB signaling and NLRP3 inflammasome[J]. Neuroscience, 2017, 360:48-60. [15] YU SX, CHEN W, HU XZ, et al. Liver X receptors agonists suppress NLRP3 inflammasome activation[J]. Cytokine,2017, 91:30-37. [16] ENJOJI M, YADA R, FUJINO T, et al. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis:the role of MDR3 expression[J]. Hepatol Int, 2009, 3(3):490-496. [17] HEO W, LEE ES, CHO HT, et al. Lactobacillus plantarum LRCC5273 isolated from Kimchi ameliorates diet-induced hypercholesterolemia in C57BL/6 mice[J]. Biosci Biotechnol Biochem, 2018,82(11):1964-1972. [18] DU J, XIANG X, LI Y, et al. Molecular cloning and characterization of farnesoid X receptor from large yellow croaker(Larimichthys crocea)and the effect of dietary CDCA on the expression of inflammatory genes in intestine and spleen[J]. Comp Biochem Physiol B Biochem Mol Biol, 2018, 216:10-17. [19] LI G, KONG B, ZHU Y, et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice[J]. Toxicol Appl Pharmacol, 2013, 272(2):299-305. [20] HAO H, CAO L, JIANG C, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis[J]. Cell Metab, 2017, 25(4):856-867. e5. [21] ZHANG Y, JACKSON JP, ST CLAIRE RL 3rd, et al. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes[J]. Pharmacol Res Perspect, 2017, 5(4):e00329. [22] WU SY, CUI SC, WANG L, et al. 18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway[J]. Acta Pharmacol Sin, 2018, 39(12):1865-1873. [23] KIM KH, CHOI JM, LI F, et al. Xenobiotic nuclear receptor signaling determines molecular pathogenesis of progressive familial intrahepatic cholestasis[J]. Endocrinology, 2018, 159(6):2435-2446. [24] ZHANG T, LIU Y, ZENG R, et al. Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation[J]. Liver Int, 2018, 38(4):724-732. [25] KITTAYARUKSAKUL S, ZHAO W, XU M, et al. Identification of three novel natural product compounds that activate PXR and CAR and inhibit inflammation[J]. Pharm Res, 2013, 30(9):2199-2208. [26] SHAH P, GUO T, MOORE DD, et al. Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters[J]. Drug Metab Dispos, 2014, 42(1):172-181. [27] TANNER N, KUBIK L, LUCKERT C, et al. Regulation of drug metabolism by the interplay of inflammatory signaling, steatosis, and xeno-sensing receptors in HepaRG cells[J]. Drug Meta Dispos, 2018, 46(4):326-335. [28] LICKTEIG AJ, ZHANG Y, KLAASSEN CD, et al. Effects of absence of constitutive androstane receptor(CAR)on bile acid homeostasis in male and female mice[J]. Toxicol Sci, 2019,21:1-14. [29] WANG YG, ZHOU JM, MA ZC, et al. Pregnane X receptor mediated-transcription regulation of CYP3A by glycyrrhizin:A possible mechanism for its hepatoprotective property against lithocholic acid-induced injury[J]. Chem Biol Interact, 2012, 200(1):11-20. [30] FUJIWARA R, CHEN S, KARIN M, et al. Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia[J]. Gastroenterology, 2012, 142(1):109-118. e2. [31] HARADA K, ISSE K, KAMIHIRA T, et al. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis[J]. Hepatology, 2005, 41(6):1329-1338. [32] DAI M, HUA H, LIN H, et al. Targeted metabolomics reveals a protective role for basal PPARαin cholestasis induced byα-naphthylisothiocyanate[J]. J Proteome Res, 2018, 17(4):1500-1508. [33] ZHANG Y, ZHANG Y, KLAASSEN CD, et al. Alteration of bile acid and cholesterol biosynthesis and transport by perfluorononanoic acid(PFNA)in mice[J]. Toxicol Sci, 2018, 162(1):225-233. [34] YAMAGUCHI R, SAKAMOTO A, YAMAMOTO T, et al. Di-(2-ethylhexyl)phthalate suppresses IL-12p40 production by GMCSF-dependent macrophages via the PPARα/TNFAIP3/TRAF6axis after lipopolysaccharide stimulation[J]. Hum Exp Toxicol,2018, 37(6):596-607. [35] KEMPINSKA-PODHORODECKA A, MILKIEWICZ M, WASIK U, et al. Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDRmiRNA155-SOCS1 pathway[J]. Int J Mol Sci, 2017, 18(2):e289. [36] ZHANG M, LIN L, XU C, et al. VDR agonist prevents diabetic endothelial dysfunction through inhibition of prolyl isomerase-1-mediated mitochondrial oxidative stress and inflammation[J]. Oxid Med Cell Longev, 2018, 2018:1714896. [37] POLS T, PUCHNER T, KORKMAZ HI, et al. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor[J]. PLoS One, 2017,12(5):e0176715. [38] SACTA MA, THARMALINGAM B, COPPO M, et al. Genespecific mechanismsdirectglucocorticoid-receptor-driven repression of inflammatory response genes inmacrophages[J]. Elife, 2018, 7:e34864. [39] HU X, WANG Y, SHEIKHAHMADI A, et al. Effects of glucocorticoids on lipid metabolism and AMPK in broiler chickens’ liver[J]. Comp Biochem Physiol B Biochem Mol Biol,2019, 232:23-30. [40] WANG X, WANG F, LU Z, et al. Semi-quantitative profiling of bile acids in serum and liver reveals the dosage-related effects of dexamethasone on bile acid metabolism in mice[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1095:65-74. [41] TAKIGAWA T, MIYAZAKI H, KINOSHITA M, et al. Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 305(6):g427-g438.
计量
- 文章访问数: 794
- HTML全文浏览量: 36
- PDF下载量: 134
- 被引次数: 0